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Роль коагулопатии при тяжелой новой коронавирусной инфекции еще предстоит выяснить. Механизмы коагулопатии можно суммировать 
по двум основным направлениям: пути, обусловленные воспалением, и пути, связанные со специфическими вирусами. Частота тромбоэм-
болических событий высока, при этом тромбоэмболия легочной артерии является наиболее частым тромбоэмболическим осложнением. 
Низкомолекулярный гепарин считается основным профилактическим и терапевтическим средством у пациентов с COVID-19. Лечение 
тромбоэмболических осложнений следует начинать без промедления во всех случаях с определенным или клинически подозреваемым 
диагнозом, подтвержденным или нет определенными диагностическими методами.
В обзоре рассмотрены: механизмы развития коагулопатии при COVID-19, в том числе связанные непосредственно с действием вируса; 
диагностическая значимость биохимических маркеров и тромбоэластографии; частота встречающихся тромбоэмболических событий; 
подходы к профилактике и лечению связанной с COVID-19 коагулопатией.
Ключевые слова: тромбоэмболизм, COVID-19, венозный тромбоз, коагулопатия, лечение коагулопатии
Для цитирования: Лаврентьева A., Тсотсолис С. Тромбоэмболические осложнения при заболевании COVID-19, коротко об изменениях 
в рекомендациях // Вестник анестезиологии и реаниматологии. – 2021. – Т. 18, № 1. – С. 37-46. DOI: 10.21292/2078-5658-2021-18-1-37-46
Thromboembolic complications in COVID-19 disease, a brief update   
A. LAVRENTIEVA1, S. TSOTSOLIS2
1Papanikolaou Hospital, Thessaloniki, Greece
2Aristotle University of Thessaloniki, Thessaloniki, Greece
The role of coagulopathy in severe novel coronavirus infection remains to be clarified.  Coagulopathy mechanisms can be summarised in two main 
pathways: inflammation-related and specific-virus related pathways.  The incidence of thromboembolic events is high with pulmonary embolism 
being the most frequent thromboembolic complication. Low molecular weight heparin is considered the main prophylactic and therapeutic option 
in patients with COVID-19. Treatment of thromboembolic complications should be started without delay in all cases with certain or clinically 
suspected diagnosis, whether confirmed or not with specific diagnostic methods.
The article reviews the following: mechanisms of development of coagulopathy in COVID-19 including those directly related to the action of 
the virus, the diagnostic value of biochemical markers and thromboelastography, the incidence of thromboembolic events, and approaches to the 
prevention and treatment of COVID-19-associated coagulopathy.
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Patients with coronavirus infection are prone to de-
veloping thrombotic complications such as pulmonary 
embolism (PE), deep vein thrombosis (DVT) and ar-
terial thrombosis. This review analyzes the complex 
mechanisms of COVID-19 (coronavirus disease 2019) 
infection-associated coagulopathy, summarizes the 
incidence of venous thromboembolic events (venous 
thromboembolism, VTE), and discusses prophylaxis 
issues and therapeutic interventions in critically ill 
patients with COVID-19 infection and venous throm-
boembolic disease.
Mechanisms of coagulation dysfunction in 
COVID-19
The activation of inflammation and coagulation 
pathways constitutes a key element of COVID-19 
infection pathophysiology and clinical presentation. 
Initially, this response is appears to be part of the adap-
tive innate host defence mechanism in order to limit 
spread of the virus pathogen [1]. However, excessive 
activation of the inflammation and coagulation cas-
cade is detrimental and shown to be associated with 
increased morbidity and mortality [52, 53]. In general, 
the three components of Virchow's triad, comprised 
of endothelial injury, stasis/low blood flow and hy-
percoagulable state, represent three major qualities in 
physiology that explain the higher risk of thrombosis 
in severe COVID-19 patients [54].
Different specific mechanisms are possibly involved 
in the pathogenesis of coagulation dysfunction in pa-
tients with SARS-CoV-2 (severe acute respiratory 
syndrome coronavirus-2) infection [17]. These mech-
anisms could be briefly summarized in the following 
two main pathways: 1) inflammatory reaction-related 
pathways, 2) specific virus-related pathways.
1. Inflammatory reaction induced pathway in-
cludes the following pathophysiologic features
a. Release of the acute phase mediators of systemic 
inflammatory response
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Invasion of SARS-CoV-2 in the lung causes a 
damage of both epithelial and endothelial cells lead-
ing to high levels of pro-inflammatory cytokines 
(interleukin-1β (IL-1β), interleukin-6 (IL-6), and tu-
mor necrosis factor-α ‒ TNFα) [56, 62]. The elevated 
levels of pro-inflammatory cytokines induced by coro-
navirus infection and the activation of the innate im-
mune system constitute the so-called “cytokine release 
syndrome” and seem to be related to the most severe 
clinical manifestations of the disease [15, 33]. 
The enhanced cytokine production during virus 
infection stimulates procoagulant reactions, with in-
creased tissue factor expression, a key initiator of the 
activation of coagulation cascade [6]. Proinflamma-
tory cytokines such as interleukin (IL)-1β and IL-6 
stimulate the expression of tissue factor on immune 
cells and initiates extrinsic coagulation cascade acti-
vation. Results from clinical trials in sepsis with drugs 
targeting these pathways, showed that IL-6 rather 
than TNF seems to be the most important mediator 
for cytokine-induced coagulation activation [20]. In-
terleukin-6 is a multifunctional cytokine that is as-
sociated with the synthesis of other coagulation fac-
tors such as fibrinogen and factor VIII [49, 50]. IL-6 
is believed to be linked to vascular endothelial growth 
factor (VEGF) expression on endothelial cells, induc-
ing endothelial damage through transcriptional control 
mechanisms and further accelerating the prothrom-
botic reactions [7].
Data suggest that complement cascade activation as 
well as other acute phase components of the systemic 
inflammatory response could also mediate thrombotic 
microvascular injury in COVID-19 patients [3, 20, 30].
b. Release of von Willebrand factor containing ul-
tra-large multimers
COVID-19-related proinflammatory cytokines 
cause direct endothelial injury resulting in ultralarge 
von Willebrand factor multimers (ULVWF) release 
from endothelial storage, the overexpression of tissue 
factor (TF) and the activation of platelets and neutro-
phils [52, 56, 62]. VWF containing ultra-large multim-
ers has been shown to have the highest binding affinity 
to platelets, thus facilitating rapid platelet accumula-
tion to sites of vascular injury and exposed subendothe-
lial structures such as collagen [44]. VWF containing 
ultra-large multimers is also believed to be connected 
to the activation of coagulation and subsequent hyper-
coagulability state via TF/FVIIa pathway [39].
c. Suppression of fibrinolytic system and increase of 
procoagulant factors
Dysregulation of the fibrinolytic system is closely as-
sociated with multiple pathologic conditions, including 
inflammation, infection and thrombosis. Virus infection 
provokes suppression of the fibrinolytic system due to 
the decreased activity of urokinase-type plasminogen 
activator and increased release of plasminogen acti-
vator inhibitor-1 (PAI-1), which is the main modu-
lator of the fibrinolytic system. PAI-1 is synthesized 
in endothelial cells and stored in platelets. Thrombin 
generation provoked by inflammation additionally trig-
gers the generation and release of PAI-1 from platelets 
leading to the supressed fibrinolysis and pathological 
fibrin deposition [13, 23]. Hypercoagulation is further 
exacerbated by an imbalance between increased lev-
els and activity of procoagulant factors (FV, FVIII, 
fibrinogen) and normal natural coagulation inhibitors 
(antithrombin III and proteins C) [2, 11, 19, 32].
2. Virus-specific pathway of coagulopathy in 
COVID-19 includes the following features
a. Direct endothelial injury
There is evidence of direct invasion of endothelial 
cells by coronavirus, potentially leading to cell injury 
[22, 28, 58]. Experimental data demonstrated that coro-
nacirus can directly infect engineered human blood ves-
sel cell organoids and human kidney cell organoids [35]. 
Post-mortem analysis of the transplanted kidney by 
electron microscopy revealed viral inclusion structures 
in endothelial cells in severe cases of SARS-CoV-2 [58]. 
Additionally, the injured endothelial cells can actively 
participate in pre-coagulation reactions. The rapid viral 
replication within endothelial cells may induce mas-
sive endothelial cell apoptosis causing the activation 
of the endothelial cell-dependent pathway of coagula-
tion [48]. Although platelets can augment thrombin 
formation by endothelial cell-dependent reactions, en-
dothelial cells damage alone can lead to formation of a 
cell-associated fibrin clot. The infected endothelial cell 
could provide an additional substrate for coagulation 
cascade initiation leading to fibrin formation.
b. Activation of the renin-angiotensin system
In addition to procoagulant and anticoagulant path-
ways dysregulation, there are data regarding the key 
role of renin-angiotensin system angiotensin-I-con-
verting enzyme 2 (ACE2) receptor in pathophysiology 
of SARS-CoV-2 [15]. Spike surface glycoprotein of 
the coronavirus binds ACE2, an integral membrane 
receptor expressed in many mammal cells, inducing 
the virus-mediated decrease in ACE2 expression and 
activation of the renin-angiotensin system (RAS). This 
mechanism could play an important role in enhancing 
platelet adhesion and aggregation and reducing fibri-
nolytic activity [31, 57].
In summary, the following four major factors acceler-
ate thrombus formation in COVID-19 infection.
1. Release of proinflammatory cytokines, mediators 
of inflammation and von Willebrand factor containing 
ultra-large multimers leads to the activation of coagula-
tion cascade. 
2. Release of plasminogen activator inhibitor-1 
provokes suppression of the fibrinolytic system. 
3. Activation of the renin-angiotensin system pro-
motes platelets activation and aggregation. 
4. Endothelial damage induced by inflammation 
and directs virus invasion further accelerates thrombus 
formation.
Markers of coagulation in COVID-19 infection
The most typical findings in patients with COVID-19 
and coagulopathy include an increased D-dimer con-
centration, a relatively modest decrease in platelet 
count, and a prolongation of prothrombin time. Based 
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on the experience from published literature, monitor-
ing PT, D-dimer and fibrinogen levels, platelet count 
are suggested to be helpful in monitoring and determin-
ing prognosis in COVID-19 patients requiring hospital 
admission.
Using the available evidence, the expert panel of In-
ternational Society on Thrombosis and Haemostasis 
(ISTH) suggests monitoring coagulopathy in patients 
with severe COVID-19 by measuring prothrombin 
time, platelet count, and D-dimer concentrations ev-
ery 2–3 days [47, 54]. However, high fibrinogen and 
D-dimer levels is known to be associated both with the 
hypercoagulable and inflammatory states. It should be 
kept in mind that D-dimer levels could not accurately 
differentiate between the presence of thromboembolic 
events and high levels due to the critical illness state 
and activation of inflammatory reaction. Consequently, 
an increase in D-dimer level is not specific for venous 
thromboembolic events and is not sufficient to make 
the diagnosis of VTE [24]. 
Updated guidelines on antithrombotic therapy 
in patients with COVID-19 declared that in hospital-
ized patients with COVID-19, hematologic and co-
agulation parameters should be commonly measured, 
although there are currently insufficient data to guide 
management decisions [36].
There are currently insufficient data to recommend ei-
ther for or against routine deep vein thrombosis screen-
ing in COVID-19 patients without signs or symptoms 
of VTE, regardless of the levels of their coagulation 
markers. Experts suggest the use of standard-of-care 
objective testing (i.e., CTPA (computed tomography 
pulmonary angiogram), V/Q (ventilation-perfusion) 
scan, MRI (magnetic resonance imaging) venography, 
Doppler ultrasonography) to diagnose VTE based on 
clinical index of suspicion. Routine screening for VTE 
using bedside Doppler ultrasonography of the lower 
extremities based on elevated D-dimer levels is not 
recommended [36, 47].
Thromboelastography findings in COVID-19 pa-
tients
Thromboelastography (TEG) is a point-of-care test 
designed to assess multiple aspects of overall clotting 
formation and dissolution in whole blood.
The most common thromboelastography (TEG) 
findings in patients with COVID-19 include short-
ened reaction time, indicating increased early throm-
bin burst, shortened clot formation time, indicating 
increased fibrin generation, increased maximum ampli-
tude, consistent with greater clot strength, and reduced 
clot lysis at 30 minutes consistent with suppression of 
fibrinolysis [39].
A few recent studies have demonstrated the ability of 
thromboelastography to identify patients at increased 
risk for VTE in COVID-19 patients with conflicting re-
sults [37, 39, 45, 61]. A study of J. R. Mortus et al. [37] 
evaluated the association of thromboelastographic 
results with hypercoagulability among critically ill 
patients with coronavirus disease 2019. Ninety per-
cent of patients demonstrated hypercoagulable TEG 
findings associated with high incidence of thrombotic 
events (62%). A hypercoagulable innate TEG MA 
yielded 100% sensitivity and 100% negative predic-
tive value for the occurrence of multiple thromboses. 
N. Salem et al. [45] observed a lower rate of hyperco-
agulable state using thromboelastography in critically 
ill patients with COVID-19 (30.8%). Additionally, the 
authors did not find a significant association between 
hypercoagulable state and thrombotic events. A study 
of E. Yuriditsky et al. [61] showed a significant propor-
tion of critically ill patients with coronavirus disease 
who demonstrated hypercoagulable thromboelastogra-
phy profiles (50%). Thirty-one percent of patients ad-
mitted to an ICU had thromboembolic events, however, 
the authors did not observe any association between 
thromboelastography variables and thromboembolic 
events in this cohort of patients. 
Further studies are necessary in order to conclude 
a causal association between the thromboelastography 
variables and the prevalence of thrombotic complica-
tions in patients with coronavirus disease.
Differential diagnosis of COVID-19 associated 
coagulopathy
Many patients with severe COVID-19 present with 
coagulation abnormalities that mimic other systemic 
coagulopathies associated with severe infections, such 
as disseminated intravascular coagulation (DIC) or 
thrombotic microangiopathy. However, COVID-19-re-
lated systemic coagulopathy presents specific pattern, 
distinct from DIC and thrombotic microangiopathy 
[2, 9, 46]. In fact, most patients with COVID-19 would 
not be classified as having DIC according to the DIC 
score of the International Society on Thrombosis and 
Haemostasis [14, 15, 18, 59]. Table 1 summarizes the 
main differences of clinical and laboratory features in 
patients with COVID-19, DIC and thrombotic mi-
croangiopathy. 
Incidence of thromboembolic events
Coagulation system changes associated with 
COVID-19 suggest the presence of a hypercoagulable 
state which, together with endothelial injury, increas-
es the risk of thromboembolic complications [40, 53]. 
In critically ill patients, the incidence of thromboem-
bolic complications ranges from 5% to 15%; initial 
cohort studies show that the incidence of thrombo-
embolic complications in patients with COVID-19 is 
as high as 21–69% [16, 21, 27, 34, 38, 41]. A study of 
F. A. Klok et al. [16] evaluated the incidence of the 
composite outcome of symptomatic acute pulmonary 
embolism, deep-vein thrombosis, ischemic stroke, myo-
cardial infarction or systemic arterial embolism in 184 
ICU patients with proven COVID-19 pneumonia; all 
patients received at least standard doses thrombopro-
phylaxis. The cumulative incidence of thrombotic com-
plications in ICU patients with COVID-19 infections 
was remarkably high (31%, 95% CI 20‒41). CTPA 
and/or ultrasonography confirmed VTE in 27% and 
arterial thrombotic events in 3.7%. PE was the most 
frequent thrombotic complication (81%). Age and co-
agulopathy, defined as spontaneous prolongation of 
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the prothrombin time > 3 s or activated partial throm-
boplastin time > 5 s were independent predictors of 
thrombotic complications.
R.A. Trigonis et al. [55] analysed data of 45 intu-
bated patients with COVID-19 who underwent ul-
trasound evaluation to identify DVT and revealed the 
overall incidence of DVT 19 of 45 patients (42.2%) 
with all noted findings being lower extremity DVT. 
The authors found that all patients with DVTs received 
prophylactic regimens consisting of both LMWH and 
unfractionated heparin and there was no relationship 
between different prophylactic anticoagulation treat-
ment and diagnosis of DVT.
C. Lodigiani et al. [27] studied data of 388 consecu-
tive symptomatic patients (16% requiring intensive 
care) with proven COVID-19 admitted to a university 
hospital in Milan, Italy. The primary outcome includes 
thromboembolic complication (venous thromboembo-
lism, ischemic stroke, and acute coronary syndrome). 
Thromboprophylaxis was used in all of ICU patients 
and 75% of patients admitted to the general wards. 
Thromboembolic events occurred in 28 patients, cor-
responding to a cumulative rate of 21% (27.6% ICU, 
6.6%  general ward). Diagnosis of venous thrombo-
embolism was confirmed in 36% of all patients tested 
with VTE imaging tests and pulmonary embolism was 
confirmed in 33% of patients who underwent CTPA. 
P. Demelo-Rodríguez et al. in a prospective study 
including 156 consecutive patients hospitalized in 
non-intensive care units with diagnosis of COVID-19 
pneumonia and D-dimer levels > 1,000 ng/ml, screened 
for asymptomatic DVT with compression ultrasound 
(CUS) [8]. Doppler imaging test was positive for DVT 
in 23 patients (14.7%), of whom seven patients (4.5%) 
had bilateral distal DVT. Patients with DVT had higher 
median D-dimer levels: 4,527 ng/ml vs 2,050 ng/ml; 
p < 0.001. D-dimer levels > 1,570 ng/ml were associat-
ed with asymptomatic DVT (OR 9.1; 95% CI 1.1–70.1).
A prospective cohort study, including patients re-
ferred to 4 intensive care units (ICUs) of a French 
tertiary hospital referred to a high number of patients 
with COVID-19 ARDS developing life-threatening 
thrombotic complications, essentially pulmonary 
embolisms (16.7%), despite the use of prophylactic 
or therapeutic anticoagulation treatment [11]. Com-
parison with non-COVID-19 ARDS patients (n = 145) 
showed that COVID-19 ARDS patients (n = 77) de-
veloped significantly more thrombotic complications, 
mainly pulmonary embolism (11.7 vs. 2.1%, p < 0.008).
A systematic review and meta-analysis of 
K. Boonyawat et al. [5] evaluated the incidence of 
incidence of venous thromboembolic events in pa-
tients with COVID-19. The authors analysed data 
from 36 studies and found that critically ill patients 
requiring ICU admission had a higher incidence of 
VTE (28%) than those in a non-ICU setting (10%), 
additionally studies that incorporated the screening 
protocols had higher incidence of venous thromboem-
bolic events. The post hoc subgroup analysis revealed 
that studies from the Netherlands and France had a 
Таблица 1. Клинико-лабораторные характеристики COVID-19, ДВС и тромботической микроангиопатии
Table 1. Clinical and laboratory characteristics of COVID-19, DIC and thrombotic microangiopathy
Clinical and laboratory characteristics COVID-19 DIC Thrombotic microangiopathies
Platelets consumption Rare, mild Frequent, profound increase Frequent, profound
Fibrinogen levels Upper limits of normal Decrease Normal
D-dimer concentrations Profound increase Profound or mild increase Mild increase
International normalized ratio (INR) Mild increase Profound increase Normal/mild increase
PTT Mild increase Profound increase Normal/mild increase
Plasminogen activators, (u-PA and t-PA) Profound increase Increase in early phase,  decrease thereafter Increase
PAI-1 Increase Increase Increase
Natural anticoagulants Mild decrease Profound decrease Normal
Lactate dehydrogenase (LDH) Mild increase Mild increase Profound increase
Ferritin concentrations Profound increase Frequent Increase High concentrations
Ultra-large von Willebrand factor multimers Increase Increase Profound increase
ADAMTS13 concentrations No data Decrease Profound decrease (< 10%) in TTP
C-Reactive protein Profound increase Profound increase Increase
Hemolysis Rare Rare Frequent, profound
Schistocytes Rare Frequent Frequent, profound
Hypercytokinaemia Profound Frequent Rare
Bleeding complications Rare Frequent Frequent
Abbreviations: DIC: disseminated Intravascular Coagulation, INR: international normalized ratio, PTT: partial thromboplastin 
time, PAI-1: plasminogen activator inhibitor-1, ADAMTS13 zinc-protease: a disintegrin and metalloproteinase 
with a thrombospondin type 1 motif, member 13, TTP: thrombotic thrombocytopenic purpura, u-PA and t-PA: 
plasminogen activators urokinase-type (u-PA) and tissue-type (t-PA)
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higher pooled incidence of PE ranging from 17 to 27%, 
whereas the studies from Italy and UK reported lower 
incidence of PE, ranging from 3 to 7%. Among the 
imaging studies which reported PE events detected 
by CTPA or DVT detected by CUS, the incidences of 
PE and DVT were 26 and 33%, respectively. The dif-
ferences between studies could be explained by several 
confounding factors, such as different diagnostic ap-
proach, divergences in performing imaging tests and 
CTPA. The indications for CTPA were varied between 
studies. Most studies performed CTPA based on clini-
cal suspicion, whereas some studies based on a high 
D-dimer level or only in patients with DVT. Several 
studies did not mention performing CTPA or did not 
mention the indication for CTPA, which could under-
estimate the incidence of PE. In twelve studies with 
no leg compression ultrasound screening (CUS), the 
incidence of DVT was 6% (95% CI 4–9%), whereas in 
nine studies with CUS screening, the incidence of DVT 
was 32% (95% CI 18–45%). 
Management of COVID-19 associated coagulopa-
thy 
Prophylactic anticoagulation
An early study of Tang et al. evaluated coagulation 
status, medications, and outcome in 449 patients with 
severe COVID-19, 99 of them receiving heparin (main-
ly with low molecular weight heparin) for prophylactic 
anticoagulation. Anticoagulant therapy appears to be 
associated with better prognosis in severe COVID-19 
patients presenting coagulopathy, especially those with 
markedly elevated D-dimer (> 6-fold of upper limit of 
normal). Interestingly, the incidence of hemorrhagic 
complications in patients with COVID-19, even in 
those with severe coagulopathy, appear to be low [51]. 
In view of the hypercoagulable state of patients with 
severe COVID-19, and the potential increased risk of 
thrombosis, experts suggest that in all patients who 
require hospital admission with COVID-19 infection 
prophylactic treatment with low molecular weight hep-
arin (LMWH) should be considered in the absence of 
any medical contraindications such as active bleeding 
and low platelet count (less than 25 × 109/L); while 
monitoring is advised in patients with severe impair-
ment of renal function [47, 54]. 
Guidelines from the American College of Chest 
Physicians (ACCP) [36] suggest prophylaxis with 
LMWH or fondaparinux instead of unfractionated 
heparin or direct oral anticoagulants (DOACs) for all 
hospitalized patients with COVID-19 in the absence of 
contraindications. Once-daily injectable LMWH and 
fondaparinux, are preferred to unfractionated heparin 
(2‒3 times per day), because of the lower exposure 
of clinicians to infected patients and lower incidence 
of heparin-induced thrombocytopenia. Additionally, 
LMWH has been shown to have anti-inflammatory 
properties which may be an added benefit in COVID-19 
infection where proinflammatory cytokines are mark-
edly raised [42].
If LMWH is not available, unfractionated heparin 
could be used, although this requires more frequent 
injections; an alternative is fondaparinux, but wheth-
er this drug has the postulated anti-inflammatory 
benefits of heparin is unclear and data on the use of 
fondaparinux are scarce. Additionally, concerns were 
raised about relatively longer half-life and reversibility 
of fondaparinux compared to LMWHs [36, 47].
Both LMWH and fondaparinux are preferred to di-
rect oral anticoagulants (DOACs) because of possible 
interactions of DOACs with immunosuppressant, anti-
viral and other experimental drugs used for treatment 
of COVID-19 [36, 47].
It is still debated if the use of standard prophy-
lactic anticoagulation dosing is sufficient in pa-
tients with increased disease severity as well as in 
patients requiring ICU admission, given the high 
VTE incidence despite standard thromboprophylaxis 
[4,  26, 29]. Although higher dose of LMWHs has 
been proposed for prophylaxis in critically ill patients 
with COVID-19, the experts suggest standard-dose 
LWMH based on the absence of clinical trial data on 
this issue [47]. The ACCP states that patients with 
severe COVID-19 might need higher-dose thrombo-
prophylaxis than routinely given because of their hy-
percoagulable state [47]. However, experts highlight 
that benefit-to-risk ratio remains to be addressed in 
prospective trials, before adopting an aggressive an-
ticoagulation approach. 
The International Society on Thrombosis and He-
mostasis (ISTH) [47] suggests that half-therapeu-
tic-dose LMWH be considered for prophylaxis in 
high-risk patients with COVID-19, and that a higher 
dose be considered in patients with obesity; however, 
optimal prophylactic therapy remains unclear. Prob-
ably, a more aggressive thromboprophylaxis using 
LMWH or UFH could be considered on an individual 
basis, especially in patients with multiple risk factors 
for thromboembolism such as obesity, cancer, personal 
history of venous thromboembolism [25, 36].
Prophylactic anticoagulation in specific clinical 
scenarios
a. Genetic risk factors and prophylaxis in specific 
ethnic populations  
Data suggest that the incidence of venous throm-
boembolism is higher in Caucasian population in com-
parison to Chinese population [12, 21, 43]. Conversely, 
risk of thromboembolic complications is higher in 
American-African population compare to Caucasian 
individuals [10, 60]. Because the evidence suggests that 
the prevalence and genetic risk factors of VTE vary sig-
nificantly among ethnic populations, and the incidence 
of VTE in Asian populations is low (21‒29 cases per 
100,000 individuals per year), a higher dose of LMWH 
might be considered in non-Asian patients with severe 
COVID-19 [51].
b. Chronic anticoagulant or antiplatelet therapy 
Hospitalized patients with COVID-19 who are tak-
ing anticoagulant or antiplatelet therapy for underlying 
medical conditions should continue their treatment 
unless significant bleeding develops, or other contra-
indications are present [36].
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Therapeutic measures
Current guidelines suggest for hospitalized 
COVID-19 patients who experience sudden deterio-
ration of pulmonary, cardiac, or neurological function, 
rapid increase of oxygenation requirements, rapid 
development of right heart failure, and/or shock in 
combination with high D-dimer levels, thromboem-
bolic disease should be part of the differential diag-
nosis [36, 47]. 
In patients with COVID-19 and acute PE with car-
diopulmonary deterioration (progressive increase in 
heart rate, decrease in systolic BP, increase in jugu-
lar venous pressure, worsening gas exchange, clinical 
signs of shock i.e. cold sweaty skin, reduced urine out-
put, confusion, progressive right heart dysfunction on 
echocardiography, or increase in cardiac biomarkers) 
after initiation of anticoagulant therapy who have not 
yet developed hypotension and who have a low risk 
of bleeding, experts suggest systemic thrombolytic 
therapy in favour of no therapy [36].
In patients with a strong clinical suspicion of throm-
boembolic complications in whom no objective diag-
nosis can be obtained due to practical difficulties to 
perform the diagnostic tests in unstable patients, or due 
to the limited access to contrast-enhanced CT, thera-
peutic anticoagulation could be initiated, particularly 
in the absence of contraindications for anticoagulation 
treatment [36, 47].
Current recommendations on thromboprophylaxis 
and VTE treatment in hospitalized COVID-19 pa-
tients based on ACCM and ISTH guidelines [4, 36, 47] 
are presented in table 2.
Recommendations American College of Chest Physician (ACCP) Committee of the International society on Thrombosis and Haemostasis (ISTH)
Prophylaxis, hospitalized, 
non-critically ill patients
Use of anticoagulant thromboprophylaxis over 
no anticoagulant thromboprophylaxis  
(in the absence of a contraindication) (Suggestion)
Use of anticoagulant thromboprophylaxis over 
no anticoagulant thromboprophylaxis  
(in the absence of contraindications)
Anticoagulant 
thromboprophylaxis, 
critically ill patients/ sick ICU 
hospitalized COVID-19 patients
Use of thromboprophylaxis over no anticoagulant 
thromboprophylaxis (in the absence of 
contraindications) (Recommendation)
Routine thromboprophylaxis with prophylactic-dose 
UFH or LMWH should be used after careful assessment 
of bleeding risk
Choice of anticoagulant 
for thromboprophylaxis 
in critically ill or acutely 
ill hospitalized patients
Thromboprophylaxis with LMWH or fondaparinux over 
thromboprophylaxis with UFH. (Suggestion) 
Thromboprophylaxis with LMWH, fondaparinux 
or UFH over thromboprophylaxis with a DOAC 
(Recommendation)
Thromboprophylaxis with either UFH or LMWH 
or fondaparinux over DOACs unless there are absolute 
contraindications
Prophylactic dose in critically 
ill or acutely ill hospitalized 
patients
Standard dose anticoagulant thromboprophylaxis 
over intermediate or increased weight-based dosing) 
or full treatment dosing, per existing guidelines 
(Recommendation)
Thromboprophylaxis with prophylactic-dose UFH 
or LMWH should be used after careful assessment 
of bleed risk. Intermediate-dose LMWH can also 
be considered in high risk patients. Patients with obesity 
should be considered for a 50% increase in the dose 
of thromboprophylaxis
Duration of VTE prophylaxis 
for hospitalized COVID-19 
patients
No recommendations
Extended post-discharge thromboprophylaxis should 
be considered for all hospitalized patients with 
COVID-19 that meet high VTE risk criteria. The duration 
of post-discharge thromboprophylaxis can be 
approximately 14 days at least. Either LMWH  or a DOAC 
(i.e., rivaroxaban or betrixaban) can be used for extended 
duration thromboprophylaxis
Anticoagulant treatment, 
critically ill COVID-19 patients 
with proximal DVT or PE, 
anticoagulant drug choice
Use of parenteral over oral anticoagulant 
therapy. Use of LMWH or fondaparinux over UFH 
(Suggestion)
LMWH in the inpatient setting and DOACs 
in the post-hospital discharge setting. A change 
of anticoagulant regimen (i.e., from prophylactic 
or intermediate dose to treatment dose regimen) 
can be considered in patients without established VTE 
but deteriorating pulmonary status or ARDS
Anticoagulant treatment, 
duration
Anticoagulation therapy for a minimum duration 
of three months for COVID 19 patients with proximal 
DVT or PE (Recommendation)




No systemic thrombolytic therapy in most patients 
with COVID-19 and acute, objectively confirmed PE 




Use of systemically administered thrombolytics over 
no such therapy in patients with COVID-19 and both 
acute, objectively confirmed PE and hypotension 
(systolic BP < 90 mm Hg) with cardiopulmonary 
deterioration or signs of shock due to PE, who are not 
at high risk of bleeding (Suggestion)
No recommendations
Таблица 2. Текущие рекомендации по ведению ВТЭ у госпитализированных пациентов с COVID-19
Table 2. Current recommendations on VTE management in hospitalized COVID-19 patients
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and coagulopathy. In practice, however, the high incidence, 
as well as the complex nature and severity of thrombotic 
events occurring in critically ill patients with COVID-19 
disease emphasize the pivotal role of coagulation-targeted 
laboratory monitoring and therapeutic management.
Conclusion
It is still challenging to establish the association be-
tween the perplexed concepts of COVID-19 induced im-
mune response, inflammatory reaction, endothelial injury 
Abbreviations: LMWH: low-molecular-weight heparin; UFH: unfractionated heparin, DOAC: direct oral anticoagulant, 
DVT: deep venous thrombosis, PE: pulmonary Embolism
Recommendations American College of Chest Physician (ACCP) Committee of the International society on Thrombosis and Haemostasis (ISTH)
Thrombolysis in patients 
with high clinical suspicion 
and not obtainable imaging
Thrombolysis may be considered in select patients 
when cardiac arrest is suspected to be caused by PE 
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